



**MINISTRY OF FOREIGN AFFAIRS
OF DENMARK**
Invest in Denmark

2021

THE DANISH PHARMA AND BIOTECH INDUSTRY

www.investindk.com



DENMARK: BEST COUNTRY FOR BUSINESS




Gateway to the Nordics

Four international airports serve tourism, business and cargo. Copenhagen Airport has direct international routes to more than 184 destinations as per January, 2020, making it by far the largest airport and logistics hub in the Nordics.

#1 IN EUROPE FOR EASE OF DOING BUSINESS

The World Bank (2008-2020)

USD 60,195
GDP per capita
OECD (2020)



#3 on the OECD Better Life Index
(2020)

#1 IN THE WORLD FUTURE READINESS TO EXPLOIT DIGITAL TRANSFORMATION

IMD (2020)

22%
corporate
tax



Denmark aims to be powered entirely by
renewable sources by 2050

Strong infrastructure

Denmark has a strong infrastructure including six international airports, sea ports, bridges and an integrated railway system. Together, they enable easy distribution of goods and services to the Nordic markets.

#1 IN THE WORLD ATTRACTING AND RETAINING TALENTS

IMD (2020)

Language

9 out of 10 people
speak English and
5 out of 10 speak
German.



Lowest redundancy costs in the world

Shared #1, IMD (2020)

One of the most flexible labour markets in the world

IMD (2020)

#1 IN THE WORLD ON SOCIAL RESPONSIBILITY OF BUSINESS LEADERS

IMD (2020)

AMONG THE BEST AND MOST INNOVATIVE IN THE WORLD

As the European leader in drug development, Denmark offers attractive business solutions for foreign biotech companies. This includes R&D collaborations with Danish universities and research organisations, establishing European headquarters or entering into a strategic partnership regarding fast development or approval of your product for the European market.

The Danish biotechnology cluster is a major world player, especially in areas such as enzymes, CNS research, diabetes care and cancer research. A long-standing agricultural tradition created a research industry in Denmark more than 150 years ago and since then, research methods have continuously developed in Denmark.

The biotech industry emerged in the 1970s as a new recombinant DNA technology was published. With the help of recombinant DNA (also referred to as genetic engineering) proteins can be produced, such as human insulin and other drugs in cells that are grown under controlled conditions.

Since then, biotechnology has created more than 200 new medicines and vaccines, including drugs to treat diabetes, cancer, HIV/AIDS and autoimmune diseases. Biotechnology is also the cause of hundreds of diagnostic tests.

MEDICON VALLEY

Medicon Valley is one of Europe's top three clusters for biotech innovation alongside Cambridge in the United Kingdom and Basel in Switzerland, and it is home to the Danish biotech sector. Medicon Valley is a life science cluster, which spans the eastern part of Denmark including Copenhagen and the south-western part of Sweden. As one of Europe's top three pharma and biotech clusters, Medicon Valley attracts a constant stream of partners, researchers and investors.

PHARMA AND BIOTECH IN DENMARK

Fast, safe and cost-effective drug discovery and drug development is a reality in Denmark due to a number of favorable framework conditions:

- Denmark holds a long tradition for collaborative R&D. The Danish collaboration model is characterized by a high degree of interdisciplinary involvement, the ability to think holistically, and successful joint projects across public and private sectors.
- The Danish national health system registers the entire population “from embryo to grave”; a system that means Denmark is home to more than 500 biobanks and extensive medical records.
- Denmark is one of the fastest countries to approve clinical trials. In short, Denmark is the place to perform drug discovery and development.

REASONS FOR PLACING BIOTECH BUSINESS ACTIVITIES IN DENMARK:

- Denmark is among the countries that host the most clinical trials per capita in the world.¹
- Denmark is a world leader in biotech innovation, surpassed only by the United States.²
- One of the most R&D-intensive countries in the world, and the best in Europe regarding researcher concentration.³
- Denmark’s entrepreneurial ecosystem is the best in the EU and fourth best in the world.⁴

¹ clinicaltrials.gov

² Scientific American Worldview 2020

³ Bloomberg Innovation Index, 2019

⁴ Global Entrepreneurship Index 2019

THE EUROPEAN SPALLATION SOURCE (ESS)

ESS is one of the largest science and technology infrastructure projects being built today. The European Spallation Source is a pan-European project that will be built by at least 17 European countries with Sweden and Denmark as the host nations. The ESS facility will be built in Lund, whilst the ESS Data Management and Software Centre will be located in Copenhagen.

The facility design and construction includes the most powerful linear proton accelerator ever built, a 4-tonne, helium-cooled tungsten target wheel, 22 state-of-the-art neutron instruments, a suite of laboratories, and a super-computing data management and software development center.

AREAS OF RESEARCH EXPERTISE



Total commercial drug development pipeline in Denmark.

(Invest in Denmark, 2020)

FIRST-CLASS RESEARCH AND EDUCATION WITHIN BIOTECHNOLOGY

One of the main reasons for Denmark's stronghold within biotechnology today is the presence of world-class universities, university hospitals, research centers and private companies of various sizes, all working at the forefront of biotech research, targeting medicine as well as environmentally friendly products and solutions. Not only is research at the forefront, the Danish educational system focuses on teaching students to work together in an interdisciplinary context, resulting in efficient teamwork and innovative research and products.

R&D COLLABORATION

Another contributing factor for the Danish position within biotechnology is a very strong and unique interplay between the Danish universities and industry, both domestically and abroad. University students often work with the industry on their master thesis or PhD. In addition, it is not uncommon to see competitors joining forces to support or establish various university research centers. There is a strong culture of collaboration between universities, hospitals and companies all over Denmark.

Major Danish industry players include Novo Nordisk, Lundbeck, Leo Pharma, AlkAbelló, Genmab, Bavarian Nordic and a number of upcoming companies.

A longstanding agricultural tradition created a research industry in Denmark more than 150 years ago and since then, research methods have continuously developed in Denmark. Today, the Danish biotechnology cluster is a major world player, especially within:

Cancer - Denmark is one of the top medical countries in Europe when it comes to academic and commercial cancer research - comparable to Boston and Washington D.C.

Metabolic diseases - Denmark leads the way in metabolic disorder research, and is a pioneer in the prevention of obesity as well as in the treatment of all related illnesses.

Inflammatory & Infectious diseases - Denmark boasts strong basic research in inflammatory and infectious diseases in academic as well as industrial sectors.

CNS & Neuroscience - Denmark has a very strong Central Nerve System (CNS) and R&D focus, which includes both the academic institutions, as well as the industry.

A UNIQUE BUSINESS FRAMEWORK

- Home to more than 160 dedicated biotech companies.
- 40,000 people employed in the industry.
- More than 5,000 dedicated R&D employees in the sector.
- More than 300 biotech service providers.
- 8 universities.
- 7 science parks.
- 4 major university hospitals.

The European Spallation Source (ESS) foreseen for 2023.

DENMARK: THE GREEN FACTS



#1 IN THE WORLD
on climate change action

Environmental Performance Index, Yale University, 2020

**PRODUCED RENEWABLE
POWER BY 2019:**

47%
WIND

3%
SOLAR

0%
Greenhouse Gas
Emissions by
2050

100%
GREEN ELECTRICITY BY
2027

**#1 OECD
RENEWABLE
ENERGY TRENDS**

*World Economic
Forum 2020*

**#3 WORLD
BEST ENERGY
SYSTEM**

*World Energy
Council 2020*



64%

**DANISH HOUSEHOLDS
HEATED BY DISTRICT
HEATING**



**DENMARK AIMS TO BE POWERED ENTIRELY BY
RENEWABLE SOURCES BY 2050**

#2 IN ACHIEVING THE SDGS

SDG Index 2020

**#1: ORSTED
#2: CHR. HANSEN
#6: NOVOZYMES**

Danish corporates receive top
rankings on sustainability

Corporate Knights 2020

**GOVERNMENT
CLIMATE ACT TARGET:**

70%
reduction of CO₂ by 2030

HEADQUARTERS

Invest in Denmark
Ministry of Foreign Affairs
Asiatisk Plads 2, 1448 Copenhagen K
+ 45 33 92 11 16
idk@um.dk
www.investindk.com

ASIA-PACIFIC

Shanghai +86 21 8025 0688
Beijing +86 10 8532 9900
Tokyo +81 3 3496 3001
Bangalore +91 80 4113 6068
Seoul +82 0 2 795 4187
Taipei +886 2 2718 2101

EUROPE

Paris +33 1 4431 2121
Munich +49 89 5458 540
London +44 207 333 0200
Oslo +47 22 54 08 00
Barcelona +34 93 487 54 86

NORTH AMERICA

New York +1 212 223 4545
Silicon Valley +1 650 543 3180
Toronto +1 416 962 5661

OUR GLOBAL PRESENCE



WE LOOK FORWARD TO WELCOMING YOU TO DENMARK

INVEST IN DENMARK

Asiatisk Plads 2
DK-1448 Copenhagen K
Denmark
Tel: +45 33 92 00 00
idk@um.dk

This fact sheet has been made in cooperation with independent experts in our service provider network. The information stated here may contain errors or omissions. Invest in Denmark and our partners disclaim any and all liability for any loss or damage caused by such errors or omissions.



www.investindk.com